-
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing
biospace
March 20, 2018
?UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the closing of a $55 million Series C financing.
-
Arbor Biotechnologies Comes Out of Stealth Mode
biospace
March 19, 2018
Arbor Biotechnologies, Inc.,?headquartered in Cambridge, Massachusetts,?came out?of stealth mode yesterday with a $15.6 million Series A financing round, which closed in June 2017.
-
IDEAYA Biosciences Raises $94 Million Crossover Series B Financing
biospace
March 16, 2018
?IDEAYA Biosciences, Inc., announced today the successful completion of a $94 million crossover Series B financing.
-
Forbion Leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Syst
biospace
March 14, 2018
Forbion, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands.
-
JW Therapeutics Closes $90 Million Series A Financing
prnasia
March 09, 2018
JW Therapeutics today announced the completion of a $90 million Series A financing
-
Juno Therapeutics Spinout Raises $90M
biospace
March 09, 2018
JW Therapeutics,?headquartered in Shanghai, China, a clinical stage biopharma company?founded?by?Juno Therapeutics?and?WuXi AppTec?in 2016, closed a Series A financing worth $90 million.
-
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
biospace
March 05, 2018
?CARsgen Therapeutics today announces it has entered into a Pre-C financing framework agreement with receiving?$60M?equity investment from existing and new investors.
-
One-Year Old Dracen Pharma Raises $40.5M, Hunts for Office and Lab Space With Plans to Hire
biospace
January 31, 2018
Dracen Pharmaceuticals?raised?$40.5 million in equity financing from nine unidentified investors.
-
Filing Reveals Kendall Square's InVivo Therapeutics is Burning Through Cash Fast
biospace
January 30, 2018
With an experimental spinal cord implant trial on hold for more than six months, Cambridge, Mass.-based?InVivo Therapeutics?has been rapidly burning through cash and?may not have enough financing?to continue operations for much longer.
-
APRINOIA Therapeutics Closes US$11 Million Series B Financing to Advance Its Tau PET Imaging Tracer
prnasia
January 17, 2018
APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
